Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin; Pioglitazone
- Indications Diabetes mellitus; Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 22 Jun 2017 Status changed from recruiting to completed.
- 05 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 05 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2019.